LEXINGTON, Mass., Oct. 20, 2016 /PRNewswire/ -- Agenus Inc.
(NASDAQ: AGEN) will release its third quarter 2016 financial
results before the market opens on Thursday,
October 27, 2016. Agenus executives will host a conference
call at 11 a.m. Eastern Time the same
day.
To access the live call, dial 1-877-870-4263 (U.S.) or
1-412-317-0790 (International) and ask to be joined into the
"Agenus Third Quarter 2016 Earnings Call." The call will also be
webcast and will be accessible from the Company's website at
www.agenusbio.com/webcast. A replay of the webcast will be
available on the Company's website for approximately 60 days after
the call.
About Agenus
Agenus is an immuno-oncology company focused on the discovery
and development of revolutionary new treatments that engage the
body's immune system to benefit patients suffering from cancer. By
combining multiple powerful platforms, Agenus has established a
highly integrated approach for the discovery, development and
manufacture of monoclonal antibodies that modulate targets of
interest. In addition, the Company's cancer vaccine program
includes three proprietary platforms focused on individualized and
off-the-shelf vaccines uniquely designed for each patient. Agenus'
broad portfolio of novel checkpoint and other immuno-modulatory
monoclonal antibodies, vaccines and adjuvants work in combination
to provide the opportunity to create best-in-class therapeutic
regimens. The Company has formed collaborations with Merck and
Incyte to discover and develop multiple checkpoint antibodies. For
more information, please visit www.agenusbio.com; information
that may be important to investors will be routinely posted on our
website.
Forward-Looking Statement
This press release contains forward-looking statements that
are made pursuant to the safe harbor provisions of the federal
securities laws, including statements regarding the Company's
anticipated timing for releasing its third quarter 2016 financial
results. These forward-looking statements are subject to
risks and uncertainties that could cause actual results to differ
materially. These risks and uncertainties include, among others,
the factors described under the Risk Factors section of Agenus'
Form 10-Q filed with the Securities and Exchange Commission on
August 4, 2016. Agenus cautions
investors not to place considerable reliance on the forward-looking
statements contained in this release. These statements speak only
as of the date of this press release, and Agenus undertakes no
obligation to update or revise the statements, other than to the
extent required by law. All forward-looking statements are
expressly qualified in their entirety by this cautionary
statement
Contact:
Agenus:
Agenus Inc.
Michelle Linn, 781-674-4541
michelle.linn@agenusbio.com
Logo - http://photos.prnewswire.com/prnh/20160901/403578LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/agenus-to-report-third-quarter-2016-financial-results-on-october-27-2016-conference-call-to-follow-300348039.html
SOURCE Agenus Inc.